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ABSTRACT

This retrospective single-center study of a cohort of adult patients who
received voriconazole with a steady-state trough concentration measured during
therapy evaluated the rate of therapeutic trough attainment using adjusted body
weight (AdjBW)-based and total body weight (TBW)-based dosing in overweight and
obese patients. Of the 130 patients included, 45 patients received TBW-based dosing
and 85 patients received AdjBW-based dosing. Therapeutic trough attainment was
signiﬁcantly improved with AdjBW-based dosing compared to TBW-based dosing
(64.7% versus 46.7%; P = 0.047).
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oriconazole, an expanded-spectrum triazole antifungal, has a narrow therapeutic
index, saturable metabolism, variable absorption, and nonlinear kinetics requiring
therapeutic drug monitoring (TDM) to ensure safety and efﬁcacy (1–5). Weight-based
dosing, calculated with total body weight (TBW), ideal body weight (IBW), or adjusted
body weight (AdjBW), is recommended, but there is no standard dosing weight for
obese patients (1, 4, 6, 7). Data for obese patients, primarily deﬁned as those with a
body mass index (BMI) of $35 kg/m2, have shown associations between TBW-based
dosing with supratherapeutic concentrations and AdjBW-based dosing with therapeutic concentrations (8–11).
In 2015, Barnes-Jewish Hospital (BJH) enacted an AdjBW dosing protocol for
patients weighing $120% of their IBW; this threshold was chosen to be consistent with
dosing for other drugs (e.g., aminoglycosides) and with an assumption that AdjBW dosing would be appropriate for overweight and obese patients. The objective of this
study was to compare the rate of therapeutic trough attainment between TBW-based
and AdjBW-based dosing in patients weighing $120% of their IBW.
This retrospective single-center cohort included patients $18 years of age weighing
$120% of their IBW admitted to BJH between 1 August 2009 and 31 May 2018 who
received voriconazole with a steady-state trough concentration. Patients with IBWbased dosing, a diagnosis of cirrhosis, total bilirubin levels of .5 times the upper limit
of normal, or concomitant medications known to strongly inﬂuence voriconazole
metabolism were excluded.
Eligible patients were separated into treatment arms based on AdjBW- or TBWbased dosing. The loading and maintenance doses administered were divided by the
patient’s IBW, TBW, and AdjBW at the time of admission to produce the patient’s dose
in milligrams per kilogram of body weight. The dosing strategy for each patient was
the weight that produced the dose closest to a 6-mg/kg loading dose and 4-mg/kg
maintenance dose.
The ﬁrst trough concentration, deﬁned as a concentration collected 10 to 14 h after
a dose, drawn at steady state was used for comparison. Steady state was deﬁned as a
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trough concentration drawn at least 48 h after the ﬁrst loading dose if the patient
received loading doses of 6 mg/kg every 12 h for two doses or at least 5 days after
voriconazole initiation if no loading doses were administered (9–11).
The primary endpoint was the rate of therapeutic trough attainment (1 to 6 mg/liter), using AdjBW-based dosing compared to TBW-based dosing in patients weighing
$120% of their IBW (1). Secondary outcomes included the rate of subtherapeutic (less
than 1 mg/liter) and supratherapeutic (greater than 6 mg/liter) troughs between
groups (1). Subgroup analyses were performed to compare outcomes based on the
World Health Organization obesity categories (12).
Outcomes were compared using chi-square or Fisher’s exact test for nominal data
and Student's t test or Mann-Whitney U test for continuous data. Statistical signiﬁcance
was deﬁned by a P value of ,0.05.
Inclusion criteria were met by 130 of the 821 patients who had a voriconazole
trough concentration, including 85 patients in the AdjBW group and 45 patients in the
TBW group (Fig. 1). Baseline characteristics were similar between groups, except that
patients in the AdjBW group had higher weights (Table 1).
Therapeutic trough attainment was signiﬁcantly improved with AdjBW-based dosing
in patients weighing $120% of their IBW (46.7% versus 64.7%, P = 0.047) (Fig. 2). The
improved rate of therapeutic trough attainment with AdjBW-based dosing was maintained with a similar magnitude of improvement across all BMI subgroups (Table 2).
Patients in the TBW-based group had higher rates of supratherapeutic trough concentrations, although this did not reach statistical signiﬁcance (44.4% versus 28.2%
[P = 0.063], respectively). Overall, there was no signiﬁcant difference in the rate of subtherapeutic trough concentrations (8.9% versus 7.1% [P = 0.737], respectively).
These results show improved rates of therapeutic trough attainment and suggest
decreased rates of supratherapeutic concentrations with AdjBW-based dosing in patients
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FIG 1 Flow diagram of the patient selection process. “Eligible” refers to patients with at least one voriconazole
concentration who met initial inclusion and exclusion criteria. “Included” refers to patients with voriconazole
dosed based on total body weight (TBW) or adjusted body weight (AdjBW) with at least one steady-state
trough concentration.
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TABLE 1 Baseline demographics and voriconazole dosing and level characteristics

Result
Age (yrs) [median (IQR)]
No. (%) of males

TBW (n = 45)
61 (44, 70)
20 (44.4)

AdjBW (n = 85)
62 (52, 70)
47 (55.3)

P value
0.570
0.239

No. (%) of patients of race
Caucasian
Black
Other

38 (84.4)
5 (11.1)
2 (4.4)

74 (87.1)
8 (9.4)
3 (3.5)

0.681
0.490
0.567

Ht (in.) (mean 6 SD)
Wt (kg) [median (IQR)]
BMI (kg/m2) [median (IQR)]

66.2 6 3.53
87.1 (71.4, 96.7)
30.3 (27.2, 32.7)

67.8 6 3.92
96.2 (83.4, 109.1)
31.1 (29.6, 34.5)

0.180
0.007
0.047

No. (%) with BMI (kg/m2)
25–29.9
30–34.9
$35

20 (44.4)
17 (37.8)
6 (13.3)

28 (32.9)
40 (47.1)
16 (18.8)

0.196
0.310
0.427

No. (%) with underlying
immunosuppressiona
Hematologic malignancy
Bone marrow transplant
Solid organ transplant
Other

16 (35.6)
10 (22.2)
9 (20.0)
10 (22.2)

32 (37.6)
27 (31.8)
13 (15.3)
13 (15.3)

0.814
0.251
0.496
0.325

No. (%) with i.v. therapyb

36 (80.0)

65 (76.5)

0.765

No. (%) with dosing strategy
Loaded
Not loaded

39 (86.7)
6 (13.3)

70 (82.4)
15 (17.6)

0.525
0.525

Loading dose [median (IQR)]
In mg
In mg/kgc

526 (470, 600)
5.8 (5.6, 6.0)

464 (400, 500)
5.9 (5.7, 6.1)

0.012
0.089

Maintenance dose [median
(IQR)]
In mg
In mg/kgc

335 (300, 365)
3.9 (3.5, 4.1)

313 (250, 350)
3.9 (3.7, 4.2)

0.123
0.098

4.9 (2.2, 7.4)

4.6 (2.5, 6.7)

0.632

6.0 (3.9, 13.8)
5.9 (5.5, 8.6)

5.6 (3.4, 7.9)
10.5 (7.5, 19)

0.679
0.014

Voriconazole trough (mg/liter)
[median (IQR)]
Time to trough attainment
(days)d [median (IQR)]
Loaded
Not loaded
aHematologic

malignancy refers to patients who had not undergone a bone marrow transplant prior to
voriconazole initiation. Bone marrow transplant refers to patients with or without a hematologic malignancy
who had undergone a bone marrow transplant prior to voriconazole initiation.
bPatients receiving intravenous (i.v.) therapy at the time of voriconazole trough concentration.
cRespective dosing weight per treatment group was utilized to calculate the dose in milligrams per kilogram.
dTime to the ﬁrst voriconazole concentration obtained during the study period.

weighing $120% of their IBW, which complement and supplement the previous literature with the inclusion of both overweight and obese patients (9–11).
While previous literature showed that AdjBW leads to more appropriate voriconazole dosing, data were limited by small population sizes, narrow deﬁnitions of obesity,
use of random voriconazole concentrations, and variable deﬁnitions of steady-state
concentrations, necessitating further study. Although one may assume that only
patients at the upper extremes of BMI would beneﬁt from AdjBW-based dosing, this
study demonstrates a beneﬁt despite a broader deﬁnition of obesity.
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Our results suggest an association between TBW-based dosing and supratherapeutic concentrations in all subgroups, but statistical signiﬁcance was seen only in patients
with a BMI of 25 to 29.9 kg/m2. The inability to show a signiﬁcant difference in the
overall rate is likely the result of small sample size.
There was no signiﬁcant difference in the rate of subtherapeutic concentrations.
Four of the six patients in the AdjBW-based group with subtherapeutic concentrations
(ranging between 0.5 and 0.9 mg/liter) had therapeutic levels following dose increases.
One patient was transitioned to isavuconazole and one patient was transitioned to
posaconazole with therapeutic levels during therapy. Overall, these results suggest
that AdjBW-based dosing improves therapeutic trough attainment without increasing
the risk of subtherapeutic concentrations.
This study increases the generalizability of AdjBW-based dosing through the inclusion of overweight and obese patients weighing $120% of their IBW. Confounding
factors were also limited by strictly deﬁning trough concentrations and time to steady
state. Due to the retrospective design, some factors could not be assessed, including
genetic hepatic enzyme polymorphisms and rationale for trough concentrations.
Additionally, this study had a low rate of trough attainment, which may have led to
TABLE 2 Primary and secondary outcomes
No. (%) of patients in dosing group
Outcome
Primary outcome
Therapeutic trough attainment
BMI, 25–29.9 kg/m2
BMI, 30–34.9 kg/m2
BMI, $35 kg/m2
Secondary outcomes
Subtherapeutic trough attainment
BMI, 25–29.9 kg/m2
BMI, 30–34.9 kg/m2
BMI, $35 kg/m2
Supratherapeutic trough attainment
BMI, 25–29.9 kg/m2
BMI, 30–34.9 kg/m2
BMI, $35 kg/m2
Trough concn of 1–2 mg/liter
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TBW (n = 45)

AdjBW (n = 85)

P value

21 (46.7)
10/20 (50.0)
8/17 (47.1)
2/6 (33.3)

55 (64.7)
20/28 (71.4)
26/40 (65.0)
8/16 (50.0)

0.047
0.131
0.207
0.417

4 (8.9)
1/20 (5.0)
2/17 (11.8)
1/6 (16.7)
20 (44.4)
9/20 (45.0)
7/17 (41.2)
3/6 (50.0)
6 (13.3)

6 (7.1)
4/28 (14.3)
1/40 (2.5)
1/16 (6.3)
24 (28.2)
4/28 (14.3)
13/40 (32.5)
7/16 (43.8)
14 (16.5)

0.737
0.297
0.209
0.481
0.063
0.018
0.530
0.583
0.637
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FIG 2 Rate of therapeutic, subtherapeutic, and supratherapeutic trough concentrations in the total
population. Data are numbers (percentages) of patients with therapeutic, subtherapeutic, and
supratherapeutic trough concentrations.
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selection bias. Although it resulted in a high number of excluded patients, the low rate
of trough attainment can be explained by patients receiving prophylactic dosing,
patients receiving empirical short-term treatment, and patients admitted on established therapeutic regimens, which would limit the clinical utility of TDM.
In this study, AdjBW-based voriconazole dosing signiﬁcantly improved rates of therapeutic trough attainment compared to TBW-based dosing in patients weighing
$120% of their IBW. Increased rates of supratherapeutic trough concentrations were
associated with TBW-based dosing. Based on the results of this study and previous
literature, AdjBW-based voriconazole dosing, combined with TDM, should be strongly
considered in patients weighing $120% of their IBW.
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